After AbbVie’s stronger-than-expected Q3 results, the company expects its growth momentum to continue while it looks for smaller, strategic bolt-on deals to expand its business and pipeline.

After AbbVie’s stronger-than-expected Q3 results, the company expects its growth momentum to continue while it looks for smaller, strategic bolt-on deals to expand its business and pipeline.